阿瑞匹坦用于晚期肺癌咳嗽抑制的随机试验
本研究纳入128例晚期肺癌伴咳嗽超过2周且已使用镇咳药的患者,随机分为阿瑞匹坦联合医生选择镇咳药组或单用医生选择镇咳药组。结果显示阿瑞匹坦组第9天咳嗽视觉模拟评分和曼彻斯特肺癌咳嗽量表评分均显著优于对照组,且未增加严重不良事件。
要点
- 阿瑞匹坦可显著改善晚期肺癌患者的咳嗽症状。
- 阿瑞匹坦未增加严重不良事件。
- 阿瑞匹坦对咳嗽特异性生活质量有显著改善。
核心结论
- 阿瑞匹坦显著改善晚期肺癌患者的咳嗽,且不增加严重副作用。
研究设计与样本
- 随机对照试验,128例晚期肺癌伴咳嗽超过2周且已使用镇咳药的患者,1:1随机分组。
主要发现
- 第9天视觉模拟评分均值阿瑞匹坦组从基线68mm降至39mm,对照组从62mm降至49mm(P < .001)。
- 第9天曼彻斯特肺癌咳嗽量表评分均值阿瑞匹坦组从基线33降至23,对照组从30降至25(P < .001)。
- 总体生活质量两组无显著差异,但阿瑞匹坦组咳嗽特异性生活质量域显著改善(P = .017)。
- 阿瑞匹坦未增加严重不良事件。
关键数值与推荐
- 阿瑞匹坦用法:第1天口服125mg,第2至7天口服80mg,联合医生选择的镇咳药。
- 主要终点为第9天主观咳嗽改善,采用视觉模拟评分和曼彻斯特肺癌咳嗽量表评估。
临床怎么用
- 对于晚期肺癌伴持续咳嗽且已使用镇咳药的患者,可考虑加用阿瑞匹坦以改善咳嗽症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although cough is a common and distressing symptom in patients with lung cancer, there is almost no evidence to guide treatment. Aprepitant, a centrally acting neurokinin-1 inhibitor, significantly decreased cough frequency in a pilot study. METHODS: Patients with advanced lung cancer and cough lasting over 2 weeks despite a cough suppressant were randomized 1:1 to aprepitant 125 mg orally on day 1 and then 80 mg orally on days 2 to 7 with physician's choice of antitussive; or to physician's choice of antitussive alone. Evaluation was at baseline and on days 3, 7, 9, and 12. The primary end point was subjective cough improvement on day 9, measured by the Visual Analog Scale and Manchester Cough in Lung Cancer Scale. Secondary end points included quality of life (QoL) as measured by the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire and the EORTC Lung Cancer-Specific Quality of Life Questionnaire and toxicity. RESULTS: Between 2017 and 2018, 128 patients were randomized. Median baseline cough duration was 90 days. Mean Visual Analog Scale scores (in mm) at baseline and day 9 were 68 and 39 in the aprepitant arm and 62 and 49 in the control arm, respectively (P < .001); mean Manchester Cough in Lung Cancer Scale scores at baseline and day 9 were 33 and 23 in the aprepitant arm and 30 and 25 in the control arm, respectively (P < .001). Overall QoL was not significantly different between the two arms; however, aprepitant led to a significant improvement in the cough-specific QoL domain (P = .017). Aprepitant did not increase severe adverse events. CONCLUSIONS: Aprepitant led to a significant improvement in cough in advanced lung cancer, without increasing severe side effects. TRIAL REGISTRY: Clinical Trials Registry-India; No.: CTRI/2017/05/008691; URL: http://ctri.nic.in.
引用
- Noronha V, Bhattacharjee A, Patil VM, et al. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. Chest. 2020. PMID: 31958446. doi:10.1016/j.chest.2019.11.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。